Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuroimmunol ; 220(1-2): 69-78, 2010 Mar 30.
Article in English | MEDLINE | ID: mdl-20163878

ABSTRACT

As opioid receptors modulate proliferation and apoptosis of immune cells, we hypothesized that they could reduce malignant haematopoietic cells. After screening, we selected the human multiple myeloma LP-1 cells which express mu- (MOP-) and kappa-opioid receptors (KOP-R). U50 488 produces a modest but significant decrease in viability associated with an arrest in the G0/G1 phase, but not antagonized by NorBNI and not associated with modulation of p21(Cip1), p27(Kip1) or p53 expression. In contrast, no effect was observed with dynorphin, U69 593 and morphine. In conclusion, the anti-proliferative effects of U50 488 are not mediated by KOP-R in the LP-1 cells.


Subject(s)
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , Analgesics, Non-Narcotic/pharmacology , Hematopoietic Stem Cells/drug effects , Multiple Myeloma/drug therapy , Receptors, Opioid, kappa/agonists , fas Receptor/agonists , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Apoptosis/drug effects , Apoptosis/immunology , Cell Cycle Proteins/drug effects , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Cell Survival/physiology , Down-Regulation/drug effects , Down-Regulation/immunology , Drug Evaluation, Preclinical , Hematopoietic Stem Cells/metabolism , Humans , Multiple Myeloma/metabolism , Multiple Myeloma/physiopathology , Receptors, Opioid, kappa/metabolism , Resting Phase, Cell Cycle/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...